See the full press release here.
Impax Pharmaceuticals, a division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that the U.S. Food and Drug Administration (FDA) approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.
Impax Laboratories' President & CEO, Fred Wilkinson said "The FDA approval of RYTARY is an important new development for the treatment of Parkinson's disease and provides an extended-release carbidopa-levodopa product that treats Parkinson's disease. RYTARY is designed to address one of the most significant unmet needs for patients living with Parkinson's disease, which is to reduce the amount of time during the day when symptoms are not adequately controlled."
Today in America, there are approximately one million people living with this chronic disease. Because RYTARY contains both immediate release and extended release beads, it provides both initial and extended concentrations in a single dose - which reduces the time in which patients have uncontrolled symptoms.
Full press release.
Extended release capsules are just one of the many ways in which drug delivery has improved life for many patients. Your roadmap to success starts at DDP — the only event that delivers the perfect mix of technology, insights and innovation. Please join us at the 19th Annual Drug Delivery Partnerships, taking place in sunny Boca Raton, FL January 28-30.
To view the DDP 2015 agenda, click here.
Register now and save $100 off the current rate with the code XP2078BLOG.
No comments:
Post a Comment